Literature DB >> 28245178

Generic formulations of psychotropic medications and treatment response.

Venkat Bhat1, Howard C Margolese1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28245178      PMCID： PMC5373707          DOI： 10.1503/jpn.160004

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  17 in total

1.  An analysis of the slowdown in growth of spending for psychiatric drugs, 1986-2008.

Authors:  Tami L Mark; Cheryl Kassed; Katharine Levit; Rita Vandivort-Warren
Journal:  Psychiatr Serv       Date:  2012-01       Impact factor: 3.084

Review 2.  Switching from brand-name to generic psychotropic medications: a literature review.

Authors:  Julie Eve Desmarais; Linda Beauclair; Howard C Margolese
Journal:  CNS Neurosci Ther       Date:  2010-11-30       Impact factor: 5.243

Review 3.  The effectiveness of generic agents in psychopharmacologic treatment.

Authors:  Richard Kumet; Alan J Gelenberg
Journal:  Essent Psychopharmacol       Date:  2005

4.  Generic medications: another variable in the treatment of illnesses.

Authors:  Pierre Blier
Journal:  J Psychopharmacol       Date:  2007-07       Impact factor: 4.153

5.  AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

Authors:  C Hiemke; P Baumann; N Bergemann; A Conca; O Dietmaier; K Egberts; M Fric; M Gerlach; C Greiner; G Gründer; E Haen; U Havemann-Reinecke; E Jaquenoud Sirot; H Kirchherr; G Laux; U C Lutz; T Messer; M J Müller; B Pfuhlmann; B Rambeck; P Riederer; B Schoppek; J Stingl; M Uhr; S Ulrich; R Waschgler; G Zernig
Journal:  Pharmacopsychiatry       Date:  2011-09-27       Impact factor: 5.788

Review 6.  Rational use of generic psychotropic drugs.

Authors:  Maren Carbon; Christoph U Correll
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

7.  Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  Int J Clin Pharmacol Ther       Date:  2013-06       Impact factor: 1.366

8.  The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis.

Authors:  Stefan Unterecker; Florian Proft; Peter Riederer; Martin Lauer; Jürgen Deckert; Bruno Pfuhlmann
Journal:  Ther Drug Monit       Date:  2014-04       Impact factor: 3.681

9.  Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the Lombardy Region of Italy.

Authors:  Giorgio L Colombo; Enrico Agabiti-Rosei; Alberto Margonato; Claudio Mencacci; Carlo Maurizio Montecucco; Roberto Trevisan
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

10.  Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.

Authors:  Rani Samuel; Azizah Attard; Marinos Kyriakopoulos
Journal:  BMC Psychiatry       Date:  2013-10-04       Impact factor: 3.630
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.